Moderna Announces Development of Lyme Vaccine
According to the Market Watch article published 4.11.23, Moderna Inc. announced it is working to develop its first bacterial vaccine to protect against Lyme disease. This news was announced at Moderna’s fourth Vaccine Day, where they provided clinical and program updates.
The first of Moderna’s products to be approved by the U.S. Food and Drug Administration was its mRNA-based COVID vaccine. Moderna has two Lyme vaccine candidates, mRNA-1982 and mRNA-1975, in development to prevent disease. The two candidates are being designed to create antibodies for Borrelia species most common in the US and Europe, mRNA-1982 for Borrelia burgdorferi in the US, and mRNA-1975 for four “major” Borrelia species in Europe.
According to the article, the company stated that the “significant quality of life burden” is reflected in the number of cases of Lyme in both the US and Europe.
For More Information:
Read the Moderna News Release Here
Read more on Lyme Vaccines Here
Read the Market Watch News Article Here